Skip to main content
. Author manuscript; available in PMC: 2015 Aug 11.
Published in final edited form as: J Clin Exp Oncol. 2013;2(2):1000109.

Figure 1.

Figure 1

Schematic illustration of the molecular design and chemical structure of the covalent immunochemotherapeutic, gemcitabine-(C4-amide)-[anti-HER2/neu] synthesized utilizing a 2-stage organic chemistry reaction scheme that initially generates a gemcitabine UV-photoactivated intermediate.